Phase 4
Completed N=136
Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
Urinary Tract Diseases
Source: ClinicalTrials.gov NCT02805504 ↗
Enrolled (actual)
136
Serious AEs
8.8%
Results posted
Apr 2024
Primary outcomePrimary: Total Opioid Consumption — 16.4; 15.3 morphine equivalent
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
A prospective, randomized controlled study to determine the efficacy of liposomal bupivacaine given by local injection at all the wound sites in patients undergoing urologic surgeries.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Opioid Consumption |
16.4; 15.3 | — |
| PRIMARY Postoperative Pain Assessment |
4.6; 4.6 | — |
| PRIMARY Length of Hospital Stay |
37; 36 | — |
| PRIMARY Postoperative Complications |
6; 6 | — |
Eligibility Criteria
Inclusion Criteria
- Patients undergoing urologic surgery.
Exclusion Criteria
- Pregnant and/or nursing mothers.
- Allergy to bupivacaine.
- History of drug/alcohol abuse.
- Severe cardiovascular, hepatic, renal disease or neurological impairment.
Data sourced from ClinicalTrials.gov (NCT02805504). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.